Current Pharmacological Interventions in Panic Disorder

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)


Volume 13, 10 Issues, 2014


Download PDF Flyer




CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 96th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova
Padova
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.702
5 - Year: 3.298

Current Pharmacological Interventions in Panic Disorder

Author(s): Rafael C. Freire, Sergio Machado, Oscar Arias-Carrion and Antonio E. Nardi

Affiliation: Laboratory of Panic and Respiration, Federal University of Rio de Janeiro, Address: Rua Visconde de Piraja 407/702, Rio de Janeiro, Zip code: 22410-003, RJ, Brazil.

Abstract

The aim of this review was to summarize the recent evidences regarding the pharmacological treatment of panic disorder (PD). The authors performed a review of the literature regarding the pharmacological treatment of PD since the year 2000. The research done in the last decade brought strong evidences of effectiveness for paroxetine, venlafaxine, sertraline, fluvoxamine, citalopram, fluoxetine, clonazepam, and the relatively novel agent escitalopram. There are evidences indicating that the other new compounds inositol, duloxetine, mirtazapine, milnacipran, and nefazodone have antipanic properties and may be effective compounds in the treatment of PD. The effectiveness of reboxetine and anticonvulsants is a subject of controversy. In addition to selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines and atypical antipsychotics may be valid alternatives in the treatment of PD. Recent data indicate that augmentation strategies with aripiprazole, olanzapine, pindolol or clonazepam may be effective. D-cycloserine is a promising agent in the augmentation of cognitive behavioral therapy.

Keywords: Anti-anxiety agents, antidepressive agents, antipsychotic agents, benzodiazepines, clinical trial, cognitive therapy, comparative study, panic disorder.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 13
Issue Number: 6
First Page: 1057
Last Page: 1065
Page Count: 9
DOI: 10.2174/1871527313666140612125028
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science